Clinical Research Support
Office for Human Research Studies (OHRS)
Information Sheets
Information Sheets
| show all hide all |
IRB-Related Guidance-
DFCI IRB Requirements Relating to the Honest Broker in Biobanking
Blood Draws from Healthy Volunteers for Use in Research
Criteria for IRB Approval of Research
Deviation/Violation/Exception Reporting Policy
DFCI IRB Adverse Event Reporting Policy
DFCI IRB Policy on Receipt and Review of IND/IDE Safety Reports
DFCI IRB Two-Year Continuing Review for Qualifying Non-Federally Funded Minimal Risk Studies
Drug Shortage and Substitution during Research Studies
Partners Recruitment of Subjects Policy
Requirements to Involve Prisoners as Participants in Research
Single Patient IND and Emergency Use of a Test Article - Consent Form Guidance
-
Database for Drug Risk and Common Language for Risk & Events
- Common Language for Risks and Events
- Common Language for Drug Risks
Guidance Document: Consent Form for Continued Participation for Young Adults Who Have Reached Age 18
Instructions for Obtaining & Documenting Informed Consent of Non-English Speaking Subjects
Legally Authorized Representatives
Procedures for Monitoring Consent
Process
Requirements for Informed Consent
Short Form Translational Procedure
Withdrawal of Consent to Continue in Research
Use of Informed Consent Documents Posted to OncPro
Discussing Enrollment in a Clinical or Non-Clinical Trial with Prospective Participants - OHRS Forms and Submission Guidance
-
Frequently Asked Questions
Guidance on Completing Nursing & Pharmacy Screening Form
Determining if Project Is Human Subject Research
Guidance on Implementing Dose Escalation Changes in Phase 1 Approved Research
Guidance on Completing the Protocol Front Sheet
Guidance on Completing Endorsement Forms
Guidance on PDF Files and Electronic Signatures
Guidance on Alert Pages
Adverse Event Ranking Scale
Guidelines For Writing A Social/Behavioral Science Research Protocol
Guidelines For Writing a Specimen/Data Collection and Banking Research Protocol
Instructions on the Collection and Sharing of Data and Tissue Specimens
Linked and Anonymous Specimens
OHRS Submit Guidance
Change of PI for Leave of Absence
Guidance on Priority List
Guidance on Completing Radiation Safety Screening Form
Quick Reference for New Protocol Submissions
Statistical Guidelines for Non-Clinical Research Protocols - Law and Regulation Information Sheets
-
Expedited and Exempt Categories
Additional Protections for Children
How to Contact the FDA
Advertising Information about Clinical Trials
FDA Medical Devices Information
The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective
HIPAA Research Guidance Document
Massachusetts Law on Insurance Coverage for Clinical Trials - Miscellaneous OHRS Information Sheets
-
DF/HCC Research Administration Contacts
System Generated Study Closures Reopen Procedures
Sponsor Requests for PHI related to Adverse or Severe Adverse Events
Overview of the Operations of the DFCI Institutional Review Boards
Common Issues Holding Up Protocol Reviews
Guidelines for Sharing of Protocols
Microsoft Word Tips & Tricks
- Office for Human Research Studies (OHRS)
- Contacts
- Information for Sponsors
- Submitting A New Protocol
- Single Patient IND/Emergency Use of a Test Article
- Consent Documents
- After Initial Submission Forms
- HIPAA
- Information Sheets
- Resources for Biospecimen and Biobanking Research
- ANPRM
- FDA Guidance
- External Regulatory Guidance
- OHRS News Updates
- Oncology Protocol System and OHRS Submit
- Presentation and Training Materials
- Partners Policy and Guidance Links
- Office for Human Research Studies (OHRS)
- Quality Assurance Office for Clinical Trials (QACT)
- Clinical Trials Education Office (CTEO)
- Clinical Investigations Leadership Committee (CLC)
- Clinical Research Unit (CRU)
- Protocol Review and Monitoring System (PRMS)
- OnCore
